All Open Protocols
Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.
If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.
Brain/CNS
COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Physician Summary:
Age 3 - 21 (inclusive); Newly Dx: RT+ Vincristine +/- Carboplatin f/b Maint +/- Continuous Isotretinoin
NCCTG N0572- A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma
Group 1 (Patients NOT Undergoing Surgery) for study 2 is permanently closed effective 9/27/11
Physician Summary:
> Age 18; Recurrent Glioblastoma. Treatment: Oral Sorafenib and IV Temsirolimus
COG-ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma
Physician Summary:
< Age 22; Newly Diagnosed. Treatment: Vorinostat + RT vs Temozolomide + RT vs Bevacizumab + RT f/b Bevacizumab Maintenance
ANBL0032: Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Physician Summary:
< age 30; High Risk: Anti-GD2 Following ASCR
N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Physician Summary:
> Age 18; Staging: Co-deleted 1p/19q Anaplastic Glioma; Treatment: RT vs Temozolomide alone vs RT with concomitant & Adjuvant Temozolomide.
Breast
NSABP DMP-1: A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer
Physician Summary:
Women > Age 35; Increased risk of breast cancer as determined by physician. Intervention: Evaluate Decision Making Process for this group of women
CALGB 70806 - Vitamin D and Breast Cancer Biomarkers (limited to Saint Mary's Health Care only)
Physician Summary:
< Age 55; FSH < 20; Staging: Vitamin D Levels; Treatment: Vitamin D /Placebo
NCCTG N10C2 - Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Physician Summary:
> Age 18; Postmenopausal; History of Breast Cancer w/out Malignant Disease.
The FAMILY (Facing A Maternal Illness in Latency Years) Project
Physician Summary:
Questionnaires for mothers who have been diagnosed with breast cancer within the past 6 months and their child/children ages 6-12
70305: A Randomized Study to Prevent Lymphedema in Women Treated For Breast Cancer
Physician Summary:
Newly Diagnosed Stage I – IV: Study to Prevent Lymphedema. Tx: Step 1: Phsical Assessments and Questionnaires; Step 2: Education vs Education & PT Intervention.
CTSU NCIC MA.32 - A Phase III Randomized Trial of Metformin Versus Placebo on Recurrance and Survival in Early Stage Breast Cancer (QOL part of this study closes on November 4, 2011)
Physician Summary:
< Age 75; Staging: If high risk, Stage II except T0; Stage IIIA&C except T0 and T4. Treatment: Metformin vs Placebo
NSABP/NCIC CTC MA.32.F: Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Physician Summary:
Companion study to CTSU MA.32. Bio-Specimen Collection and Patient Questionnaires.
CTSU SCUSF 0806: Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin ®)
Physician Summary:
> Age 18 and HER2 Positive; Adjuvant or Neo-Adjuvant Patients scheduled to receive Herceptin with or after primary chemotherapy. TX: Lisinopril or Coreg or Placebo
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Physician Summary:
≥ age 18, Central HER2 Testing: RT +/- Trastuzumab
(Available at Saint Mary's Health Care, Spectrum Health and Bronson Battle Creek) RTOG 1014: A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma
Physician Summary:
> Age 18; Staging: Locally Recurrent Breast Carcinmoa. Tx: Lumpectomy f/b 3D CRT
B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Physician Summary:
< Age 50 if Stage 0-II; > Age 50 for Stage I & II if Node+ and/or ER-/PR- TX: Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI)
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Physician Summary:
Women > Age 18; Staging: 1-3 Positive Nodes; Oncotype Score Less than 25. Treatment: Chemotherapy + Endocrine Therapy vs Endocrine Therapy Alone.
SCRI BRE 186: Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Physician Summary:
> Age 18; Staging: T1-T3, N1-N2, or MO (T1NOMO excluded). Treatment: Eribulin + Trastuzumab
NSABP B-47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Physician Summary:
>Age 18; Resected Node(+) or High-Risk Node(-) HER2-Low (1+ to 2+ IHC). Treatment: Chemo (Physician’s choice: TC or AC f/b WP) Alone vs Chemo +Trastuzumab
NCCTG N0937: Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer
Physician Summary:
> Age 18; Stage IV; Treatment: Cisplatin IV on Day 1, Brostacillin IV on Day 2 Followed by a GCSF on Day 3 in 3 Week Cycles
S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy Vs. Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Physician Summary:
Any T, Any N, M1; Doctor Decides Chemo Tx /> Circ. Tumor Cells (High Risk) May Be Randomized to Switch Chemo @ first f/u Assessment. Hormonal and Bio Txs Continued Unchanged
CTSU E2108 - A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Physician Summary:
> Age 18; Stage IV; Treatment: Optimal Systemic Therapy (physician prescribed) less than 20 Weeks in Length f/b Continued Systemic Therapy or Surgery and RT for primary tumor
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Cancer Control
NSABP DMP-1: A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer
Physician Summary:
Women > Age 35; Increased risk of breast cancer as determined by physician. Intervention: Evaluate Decision Making Process for this group of women
NCCTG N10C2 - Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
Physician Summary:
> Age 18; Postmenopausal; History of Breast Cancer w/out Malignant Disease.
CALGB 70806 - Vitamin D and Breast Cancer Biomarkers (limited to Saint Mary's Health Care only)
Physician Summary:
< Age 55; FSH < 20; Staging: Vitamin D Levels; Treatment: Vitamin D /Placebo
The FAMILY (Facing A Maternal Illness in Latency Years) Project
Physician Summary:
Questionnaires for mothers who have been diagnosed with breast cancer within the past 6 months and their child/children ages 6-12
NSABP/NCIC CTC MA.32.F: Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Physician Summary:
Companion study to CTSU MA.32. Bio-Specimen Collection and Patient Questionnaires.
70305: A Randomized Study to Prevent Lymphedema in Women Treated For Breast Cancer
Physician Summary:
Newly Diagnosed Stage I – IV: Study to Prevent Lymphedema. Tx: Step 1: Phsical Assessments and Questionnaires; Step 2: Education vs Education & PT Intervention.
URCC 10055: Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment, and at Six Month Follow-Up
Physician Summary:
Invasive Breast Cancer Stage I-IIIC or High-Grade Lymphoma; Chemo Naïve. Patient to complete three Questionnaires.
CTSU SCUSF 0806: Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin ®)
Physician Summary:
> Age 18 and HER2 Positive; Adjuvant or Neo-Adjuvant Patients scheduled to receive Herceptin with or after primary chemotherapy. TX: Lisinopril or Coreg or Placebo
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Physician Summary:
≥ age 18, Central HER2 Testing: RT +/- Trastuzumab
NSABP P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Physician Summary:
> Age 18. Staging: Stage I or II, adenocarcinoma of the colon. Treatment: Rosuvastatin (Crestor) vs Placebo
MD Anderson 2007-0914A - (PREDICT) A Multi-Center Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment
Physician Summary:
Age 18-85 Years; New Course of Chemo w/Anthracycline. Treatment: BNP and Troponin I Prior to each Tx Cycle.
GOG 8199: Prospective Study of Risk-Reducing Salpingo-Oophrectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants
Physician Summary:
Substudy to GOG 0199 - Not available for new patients
N08C1: Paclitaxel-Associated Acute Pain Syndrome Natural History Study Please Note: Only Arms A & D are open.
Physician Summary:
≥ age 18; Any Staging: Standard of Care with Use of Paclitaxel
RC08C6: White Wine for Appetite Loss: A Randomized, Controlled Non-blinded Trial
Physician Summary:
Temp Closed! 2004-0024: Chemotherapy and Mindfulness Relaxation: A Randomized Trial At M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program
Physician Summary:
Chemotherapy & Mindfulness Relaxation/Randomized Trial
SWOG S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastasis Starting Zoledronic Acid Treatment
Physician Summary:
≥ age 18; Bone Mets: Assess ONJ in Patients receiving Zometa
NCCTG N09C6: Randomized Double-Blind Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy with or without Chemotherapy. (Not available at Mercy Health Partners or Battle Creek Health System)
Physician Summary:
> Age 18; Painful Mucositis; Must be receiving Radiotherapy w/ 1/3 of oral cavity included in the radiation therapy fields. Treatment: Doxepin/Placebo
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Gastrointestinal
(Saint Mary's Only) RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Physician Summary:
> Age 18; T1N1M0; T2-4, Any N, M0; Any T, and N, M1a. Treatment: Concurrent Radiation with Paclitaxel and Cisplatin, w/ or w/o Cetuximab
NCCTG N0849: Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Gastric Cardia
Physician Summary:
> Age 18. Staging: Locally Adv. Esophageal, GEJ or Gastric Cardia. Treatment: Docetaxel, Oxaliplatin, Capecitabine (Two 21 day Cycles) f/b 5-FU, Oxaliplatin, RT f/b Surgery or 5-FU, Oxaliplatin, RT f/b Surgery
SWOG S1005: A Phase II Study of MK-2206 as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Physician Summary:
> Age 18; Progression after 1st Line Reg. or Recurrent w/in 6 Mos of Adj Tx. Treatment: MK-2206
MCCRC I4T-MC-JVBT: A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Stomach
Physician Summary:
≥ Age 18; Advanced Adenocarcinoma of the Esophagus, GE Junction or Stomach. Treatment: mFOLFOX6 +/- Ramucirumab
NSABP P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Physician Summary:
> Age 18. Staging: Stage I or II, adenocarcinoma of the colon. Treatment: Rosuvastatin (Crestor) vs Placebo
CALGB 80702: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Physician Summary:
FOLFOX +/- 6 cycles vs 12 cycles Celecoxib
NSABP FC-6 - A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver. This study is open at Spectrum Health, Saint Mary's Health Care & Mercy Health Partners only
Physician Summary:
(Open at SH, SMHC and MHP Only) > Age 18; Staging: IV K-RAS Wild Type Unresectable Liver Mets; Treatment: Neoadjuvant mFOLFOX7 plus Cetuximab f/b liver mets resection
SCRI GI 154: A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients with First Line Metastatic Colorectal Cancer (mCRC)
Physician Summary:
> Age 18: Life Expectancy Greater than 12 weeks; Staging: Stage IV. Treatment: FOLFAZ & Avastin f/b Axtinib as Maintenance Until Progression or Adverse Toxicities
S0713: A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer
Physician Summary:
Neoadjuvant; Stage II-III; Oxaliplatin + Capecitibine + Cetuximab f/b Oxaliplatin + Capecitibine + Cetuximab + RT f/b Surgery
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Genitourinary
(Open at Spectrum Health, Saint Mary's Health Care and Bronson Battle Creek) RTOG 0815 - A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
Physician Summary:
> Age 18; Staging: T2b-T2c (intermediate risk); Treatment: Dose Escalated RT Alone vs. Dose Escalated RT Combined w/ Short Term Androgen Blockade
SWOG S1014: Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II
Physician Summary:
Adenocarcinoma of the Prostate; Staging: M1 Disease at time ADT intitiated. Treatment: Abiraterone Acetate + Prednisone until progression.
CALGB 90203: Randomized Phase III Study Of Neo-Adjuvant Docetaxel And Androgen Deprivation Prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy In Patients With High-Risk, Clinically Localized Prostate Cancer
Physician Summary:
≥ Age 18: LHRH + Docetaxel f/b Radical Prosatectomy w/staging PLND vs Radical Prostatectomy w/staging PLND
SWOG S0925: Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer
Physician Summary:
Staging: M1 - Visceral Disease (Liver, Lung, or other Viscera); Bone Metastasis, Lymph Node Disease Not Encompassed within a Single Radiation Therapy Port. Treatment: Bicalutamide/LHRH Agonist +/- IMC-A12
AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Physician Summary:
< age 30, Newly Dx Higher Risk: VCR, AMD, DOXO per DD4A for 2 cycles + DD4A vs Regimen M
COG-AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
Physician Summary:
< age 30; All drugs commercially provided. For Schema, contact pediatric nurses at GRCOP 616.391.1230.
AREN0321: Treatment of High Risk Renal Tumors
Physician Summary:
≤ age 30, Newly Diagnosed Stage I-IV, Chemo –vs- Surgery Only (Ancillary AREN03B2 Required)
SWOG S0931- EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
Physician Summary:
> Age 18; Intermediate high risk and very high risk group. Treatment: Everolimus or Placebo
CALGB 90601 - A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Physician Summary:
> Age 18; Staging: Unresectable Locally Advanced or Metastatic. Treatment: Gemcitabine + Cisplatin + Bevacizumab/Placebo x6 Cycles f/b Maintenance Bevacizumab/Placebo
CALGB 90802: Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors
Physician Summary:
> Age 18; Advanced Renal Cancer; Prior Tx with TKI Required; Treatment: Everolimus/Placebo vs Everolimus/Bevacizumab
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Gynecologic
GOG 8199: Prospective Study of Risk-Reducing Salpingo-Oophrectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants
Physician Summary:
Substudy to GOG 0199 - Not available for new patients
GOG 0249: A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy In Patients With High-Risk, Early Stage Endometrial Carcinoma
Physician Summary:
> Age 18; Staging: High Risk, Early Stage (I/II); Treatment: Pelvic RT vs Vaginal Cuff Brachytherapy f/b Paclitaxel/Carboplatin
GOG 0212: A Randomized Phase III Trial Of Maintenance Chemotherapy Comparing 12, Monthly Cycles Of Single Agent Paclitaxel Or Xyotax? (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse In Women With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane Chemotherapy.
Physician Summary:
Paclitaxel or Xyotax™ vs. No Treatment Until Documented Relapse
GOG-0261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy -Naive Patients with Newly Diagnositc Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Physician Summary:
> Age 18; Stage I-IV persistent or recurrent carcinosarcoma, chemotherapy naive. Treatment: Paclitaxel & Carboplatin vs Ifosfamide w/ Mesna & paclitaxel, G-CSF Support Required.
GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed By Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer
Physician Summary:
≥ age 18; Recurrent: If surgery candidate, Randomize to +/- Surgery; For all Patients: Carboplatin/Taxol vs. Carboplatin/Taxol +/- Bevacuzimab
GOG 0250 - A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF With Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF With Placebo in the treatment Of Recurrent or Advanced Leiomyosarcoma (LMS) of the Uterus
Physician Summary:
Advanced or Recurrent Leiomyosarcoma with documented Disease Progression. Treatment: Gemcitabine + Docetaxel + G-CSF + Bevacixumab/Placebo
GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel VS. Carboplatin and Palitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Physician Summary:
≥ age 18; Debulked Stage III or IVA: Cisplatin/XRT f/b Carboplatin/Paclitaxel vs Carboplatin/Palitaxel
Head and Neck
E1305: A Phase III Randomized Trial of Chemotherapy with or withoutBevacizumab In Patients with Recurrent Or Metastatic Head and Neck
Physician Summary:
≥ age 18; No Prior Chemo for Recurr or Mets: Cisplatin-doublet (phys. Choice) +/- Bevacizumab
(Available at Saint Mary's Health Care and Bronson Battle Creek) RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharnyx Cancer
Physician Summary:
> Age 18; Staging: T1-2, N2a-3, or T3-4 any N; Must be P16 Positive. Treatment: Cisplatin or Cetuximab w/ Concurrent RT
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Leukemia
8461: Cytogenetic Studies In Acute Leukemia
Physician Summary:
Previously Untreated AML, ALL, MDS: Bone Marrow and Blood Samples (Ancillary CALGB 9665 Required)
AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)
Physician Summary:
Age 0-30; Newly Diag. T-Cell ALL; Methotrexate, Nelarabine and Augmented BFM Therapy (Prerequisite AALL03B1)
AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Physician Summary:
≤ age 30; Initial Intermed-Risk Relapse of B-precursor: Standard VCR Dosing vs Intensive VCR Dosing
AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Physician Summary:
< Age 31; Relapsed B-precursor ALL, relapsed T-cell ALL and relapsed T-LL: Bortezomib w/Intensive Re-Induction Therapy
COG-ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazol to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Physician Summary:
AML Patients < Age 30; Caspofungin vs Fluconazol to Prevent Fungal Infections
E2906: Phase III Randomized Trial of Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years)
Physician Summary:
> Age 60; Newly Diagnosed AML. Treatment = Induction: Daunorubicin + Cytarabine vs Clofarabine f/b Consolidation: Cytarabine vs Clofarabine f/b Observation vs Decitabine, Option of Allogeneic STC for Some
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD.
Physician Summary:
< Age 30; Contact GRCOP pediatric nurses at 391-1230 for additional information on this study.
COG-AAML07P1: A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia
Physician Summary:
≤ age 21; Recurrent, Refractory or Secondary AML: Bortezomib Combined w/ Reinduction Chemotherapy
SWOG S0535: A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Physician Summary:
>18: ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Lung
Temp Closed! S0720: Phase II ERCC1 And RRM1-Based Adjuvant Therapy Trial In Patients With Stage I Non-Small Cell Lung Cancer (NSCLS)
Physician Summary:
≥ age 18; Stage 1A (w/ tumors > 2 cm) or Stage 1B: Genetic Testing for Risk. Low Risk = Observation only. High Risk = Cisplatin/Gemcitabine
(Available at Saint Mary's & Spectrum Health Only) RTOG 0813 - Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Physician Summary:
> Age 18; NSCLC Stage T1-2, N0, M0; Treatment: SBRT (Stereotactic Lung Radiotherapy)
CTSU E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4cm) – IIIA Non-Small Cell Lung Cancer (NSCLS)
Physician Summary:
≥ age 18; Stage IB to IIIA: Cisplatin w/choice of Vinorelbine, Taxotere or Gemcitabine +/- Bevacizumab
SWOG S0819 - A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Physician Summary:
> Age 18; Stage IV; Tx: Paclitaxel + Carboplatin + Bevacizumab (if appropriate) +/- Cetuximab
SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) - (Platinum Refractory Stratum closed to accrual)
Physician Summary:
E-SCLC/ > age 18; Extensive Stage, 2nd line SCLC: Topotecan +/- AVE0005
CALGB 30801 – A Randomized Phase III Double Blind Trial Evalutating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Physician Summary:
Eligibility: > Age 18; Stage IIIB or IV; Treatment: Squamous = Gemcitabine + Carboplatin + Celecoxib/Placebo; Non-Squamous = Pemetrexed + Carboplatin + Celecoxib/Placebo
RTOG 0937-Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC). (Available at Spectrum Health and Saint Mary's Health Care Only)
Physician Summary:
> Age 18; Stage IV. Treatment: Prophylactic RT following SOC Chemotherapy
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Lymphoma
COG- AHOD0831 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma
Physician Summary:
< Age 21; Stage III/IV w/ B Symptoms; Newly Diagnosed: See Fast Facts for Tx Schema. Call Pediatric Nurses at 616.391.1230 with questions.
SWOG S0816 - A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging
Physician Summary:
Age 18-60; Stage III/IV: ABVD x2 Cycles f/b PET f/b ABVD x4 or BEACOPP x6
CALGB 50901: A Phase II Trial of Ofatumumab in Previously Untreated Follicular Non-Hodgkin Lymphoma
Physician Summary:
> Age 18; WHO classification Grade 1, 2, or 3a w/out histologic transformation that is stage III, IV or bulky stage II & Low or Intermediate-Risk Disease; FLIPI Score. Treatment: Ofatumumab
SWOG S0806: A Phase I/II Trial of Vorinostat (SAHA) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Physician Summary:
> Age 18; Stage II Bulky, Stage III or Stage IV Disease w/ an IPI or R-IPI Score Greater than 0. Treatment: RCHOP + Vorinostat
AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Physician Summary:
< Age 31; Relapsed B-precursor ALL, relapsed T-cell ALL and relapsed T-LL: Bortezomib w/Intensive Re-Induction Therapy
Melanoma
This study is temp closed. E1609: Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
Physician Summary:
> Age 18; Stage IIIB-IV. Treatment: Ipilimumab vs Interferon Alpha. All physicians must complete study specific training prior to patient enrollment
Temp Closed to Premenopausal Women. NCCTG N0879 – A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab with or without Everolimus for Therapy for Metastatic Malignant Melanoma
Physician Summary:
> Age 18; Stage IV; First & Second Line Therapy, Bevacizumab, Taxol, Carboplatin +/- Everolimus
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Myeloma
SCRI MM 23 – A Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients with Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Physician Summary:
> Age 18: MM Who are not Candidates for High Dose Chemotherapy; First Line Treatment of Bendamustine + Bortezomib+ Dexamethasone
Sarcoma
COG-AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.
Physician Summary:
Age: 0-50; Non-Metastatic. Contact GRCOP Pediatric Oncology nurses at 616.486.6156 for additional information.
ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Physician Summary:
Newly Dx, < 50 years old: VAC +/- XRT
ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).
Physician Summary:
< age 50; Newly Diagnosed: VAC vs VAC alternating w/ VI; Includes XRT
AOST0331: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy
Physician Summary:
≤ age 40; High Grade Osteosarcoma: Resectable/Histological Response to Pre-Operative Chemotherapy
AOST06P1: Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma
Physician Summary:
≤ age 40; No Prior Chemo; Feasibility & Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemo
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis
Unknown Primary
N0871: A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)
Physician Summary:
> age 18; Carboplatin, Paclitaxel and Everolimus (RAD001) (Gene assay results provided at progression)
RTOG 0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis (Spectrum Health Only)
Physician Summary:
> Age 18; Stage IV - Multisite. Treatment: Image-Guided SBRT vs External Beam RT for Localized Spine Metastasis